DENVER – Immunohistochemistry (IHC) is an effective tool that can be used for identifying proto-oncogene 1 receptor tyrosine kinase (ROS1) gene rearrangements and screening patients for the administration of the targeted therapy crizotinib, a small-molecule tyrosine kinase inhibitor.
DENVER –A pre-competitive consortia of pharmaceutical companies, diagnostic companies, and academic associations, including the International Association for the Study of Lung Cancer (IASLC), announced phase I results of the “BLUEPRINT PD-L1 IHC ASSAY COMPARISON PROJECT” at the Annual Meeting of the American Association for Cancer Research (AACR) on April 19. The study compared four PD-L1 IHC diagnostic assays developed in conjunction with four PD-1/PD-L1 immune checkpoint inhibitors, which are used in non-small cell lung cancer (NSCLC) clinical trials.
DENVER – Capturing and summarizing the remarkable progress in lung cancer prevention, diagnosis, staging, and treatment in 2015, the International Association for the Study of Lung Cancer (IASLC) announces the inaugural publication of “Scientific Advances in Lung Cancer 2015” in the May 2016 issue of the IASLC’s Journal of Thoracic Oncology (JTO).
ELCC 2016: Patients with EGFR expressing non-small-cell lung cancer benefit most from necitumumab added to chemotherapy
GENEVA, Switzerland, 15 April 2016 – Patients with epidermal growth factor receptor (EGFR) expressing advanced squamous non-small-cell lung cancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis from the SQUIRE trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.
ELCC 2016: Studies confirm benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer
GENEVA, Switzerland, 15 April 2016 – The benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer (NSCLC) is confirmed in three studies presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.1 Researchers however warned that plasma tests are unlikely to fully replace tissue biopsies.
ELCC 2016: Immunotherapy with live bacterium improves response rate in malignant pleural mesothelioma
GENEVA, Switzerland, 14 April 2016 – Immunotherapy with a live bacterium combined with chemotherapy demonstrated more than 90% disease control and 59% response rate in patients with malignant pleural mesothelioma (MPM), according to the results of a phase Ib trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.